Entrada Q1 net loss $6.7M, cash $411.6M; advancing Duchenne pipeline despite clinical hold

Entrada Therapeutics, Inc.

2023-Q1 EPS reported -$0.21 revenue$25,260,000

Cash, cash equivalents and marketable securities $411.6M at March 31, 2023, up from $188.7M at Dec 31, 2022.
Collaboration revenue from Vertex deal $25.3M in Q1; net loss improved to $6.7M from $21.7M in Q1 2022.
Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; eligible for up to $485M milestones plus royalties.
ENTR-601-44 IND on clinical hold with FDA; pursuing global healthy volunteer trial initiation in 2023.
ENTR-601-45 selected as second Duchenne candidate; IND submission planned for Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Entrada Therapeutics, Inc. reported first quarter ending March 31, 2023 results: revenue $25.3 million, net income ($6.7) million.

Period: first quarter ending March 31, 2023
Revenue: $25.3 million
Net income: ($6.7) million
Result: reported results

Exact text from the filing

development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases. Collaboration Revenue: Collaboration revenue was $25.3 million for the first quarter of 2023 following the closing of the Vertex Agreement in February 2023. There was no collaboration revenue in the first quarter of 2022. Research &

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.